Weight-Loss Jabs Halve Obesity-Related Cancer Risk in Large Study

Recent research indicates that GLP-1 receptor agonists, weight-loss injections such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro), may significantly reduce the risk of obesity-related cancers beyond the benefits of weight reduction alone. Studies tracking thousands of patients have shown these drugs to be approximately 41% more effective at preventing cancer compared to equivalent weight loss achieved through bariatric surgery, suggesting additional protective mechanisms likely related to reduced inflammation and immune system effects. Experts caution that while the findings are promising, more extensive clinical trials are needed to fully understand these drugs' anti-cancer properties and ensure they do not increase risks of other cancers. The potential of these medications to serve as a preventive measure against cancer, even in non-obese individuals with risk factors, marks a possible new era in cancer prevention and treatment. However, some researchers note that current evidence is observational, warranting careful interpretation and further rigorous investigation. The prospect of mass prescription of these drugs could have significant public health and economic impacts, especially given the rising incidence of obesity-related cancers.